


Parkinson's Disease Therapy

Updated November 2024

These are examples of a stepwise approach to Parkinson's disease therapy.¹⁻¹² It is not inclusive of all therapy options. Dopamine agonists = ropinirole, pramipexole, rotigotine; MAO-B inhibitors = selegiline, rasagiline, safinamide; COMT inhibitors = tolcapone, entacapone, opicapone.



a. Combination therapy preferred when levodopa daily dose exceeds 600 mg.

b. Use this chart to see how carbidopa/levodopa products stack up. Information is from product labeling.

Trade name/formulation	Strengths available	Comments/cost
Carb/levo IR tablet (<i>Sinemet</i>)	10/100 mg, 25/100 mg, 25/250 mg	Brand no longer available in Canada. US: <\$1; Canada: <\$1
Carb/levo ER tablet (<i>Sinemet CR</i>)	25/100 mg, 50/200 mg	Brand no longer available US: <\$1; Canada: <\$5
Carb/levo IR scored tablet (<i>Dhivy</i> [US])	1 tab=25/100 mg, ¾ tab=18.75/75 mg, ½ tab =12.5/50 mg, ¼ tab=6.25/25 mg	Triple-scored tablet for ease of titration and swallowing. US: <\$5
Carb/levo orally disintegrating tablet (ODT) (<i>Parcopa</i> [US])	10/100 mg, 25/100 mg, 25/250 mg	Brand no longer available. ODT for swallowing difficulty. US: <\$5
Carb/levo IR/ER capsule (<i>Rytary</i> [US])	23.75/95 mg, 36.25/145 mg, 48.75/195 mg, 61.25/245 mg	Capsule contains IR and ER beads. US: <\$10
Carb/levo/entacapone IR tablet (<i>Stalevo</i>)	12.5/50/200 mg, 18.75/75/200 mg, 25/100/200 mg, 31.25/125/200 mg, 37.5/150/200 mg, 50/200/200 mg (US)	Eases pill burden. Generic available in US. US: <\$5; Canada: <\$5
Carb/levo ER capsule (<i>Crexont</i> [US])	35/140 mg, 52.5/210 mg, 70/280 mg, 87.5/350 mg	Biphasic release (DO NOT OPEN) US: <\$5

c. **US** cost is wholesale acquisition cost (WAC) of highest-strength tablet/capsule (generic if available). Medication pricing by Elsevier, accessed November 2024. Canadian cost is wholesale.

Parkinson's Disease Therapy

Updated November 2024

References

1. Zimmerman KM, Whitmire N. Parkinson's disease and other movement disorders. In: Zeind CS, Carvalho MG, editors. Applied Therapeutics: the Clinical Use of Drugs. 11th ed. Philadelphia, PA: Wolters Kluwer Health, 2018: 1246-72.
2. Freitas ME, Hess CW, Fox SH. Motor complications of dopaminergic medications in Parkinson's disease. *Semin Neurol.* 2017 Apr;37(2):147-57.
3. Pringsheim T, Day GS, Smith DB, et al. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. *Neurology.* 2021 Nov 16;97(20):942-957.
4. Robottom BJ. Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease. *Patient Prefer Adherence.* 2011 Jan 20;5:57-64.
5. Grimes D, Fitzpatrick M, Gordon J, et al. Canadian guideline for Parkinson disease. *CMAJ.* 2019 Sep 9;191(36):E989-E1004.
6. Parkinson's Foundation. COMT inhibitors. <https://www.parkinson.org/Understanding-Parkinsons/Treatment/Prescription-Medications/COMT-Inhibitors>. (Accessed November 20, 2024).
7. Product information for Nourianz. Kyowa Kirin. Princeton, NJ 08540. March 2023.
8. Product information for Xadago. MDD US Operations. Rockville, MD 20852. August 2021.
9. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. *Eur J Neurol.* 2013 Jan;20(1):5-15.
10. DeMaagd G, Philip A. Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. *P T.* 2015 Oct;40(10):668-79.
11. Product information for Inbrija. Acorda Therapeutics. Ardsley, NY 10502. August 2020.
12. Product monograph for Onstryv. Valeo Pharma. Kirkland, QC H9H 4R9. December 2020.

Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.

Copyright © 2024 by Therapeutic Research Center. All Rights Reserved. trchealthcare.com